CN115667309A - 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病 - Google Patents

使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病 Download PDF

Info

Publication number
CN115667309A
CN115667309A CN202180037656.9A CN202180037656A CN115667309A CN 115667309 A CN115667309 A CN 115667309A CN 202180037656 A CN202180037656 A CN 202180037656A CN 115667309 A CN115667309 A CN 115667309A
Authority
CN
China
Prior art keywords
ifn
patient
patients
disease
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037656.9A
Other languages
English (en)
Chinese (zh)
Inventor
D·西尼巴尔迪
W·怀特
M·史密斯
K·凯西
G·伊莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN115667309A publication Critical patent/CN115667309A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180037656.9A 2020-05-29 2021-05-28 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病 Pending CN115667309A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031854P 2020-05-29 2020-05-29
US63/031854 2020-05-29
PCT/EP2021/064312 WO2021239928A2 (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease

Publications (1)

Publication Number Publication Date
CN115667309A true CN115667309A (zh) 2023-01-31

Family

ID=76269736

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037656.9A Pending CN115667309A (zh) 2020-05-29 2021-05-28 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病

Country Status (10)

Country Link
US (1) US12410254B2 (https=)
EP (2) EP4157873A2 (https=)
JP (1) JP2023527054A (https=)
KR (1) KR20230018446A (https=)
CN (1) CN115667309A (https=)
AU (1) AU2021279277A1 (https=)
BR (1) BR112022023438A2 (https=)
CA (1) CA3183611A1 (https=)
IL (1) IL298299A (https=)
WO (1) WO2021239928A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
WO2022106460A2 (en) * 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
CN120392997A (zh) 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863546A (zh) * 2003-08-04 2006-11-15 布里斯托尔-迈尔斯.斯奎布公司 用可溶性ctla4分子治疗心血管疾病的方法
CN101952454A (zh) * 2008-02-08 2011-01-19 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
CN107110939A (zh) * 2014-09-11 2017-08-29 力保科学公司 使用包括hdl和炎症生物标志相互作用参数的风险参数的心血管风险评估
WO2019043292A1 (en) * 2017-08-29 2019-03-07 Gleap Health Technologies Oy METHODS AND ARRANGEMENT OF THRESHOLD DEVICE OF PHYSICAL ACTIVITY REDUCING THE RISKS OF DIABETES, CARDIOVASCULAR DISEASES, INFLAMMATIONS, DEMENTIA, CANCERS AND MORTALITY IN SEDENTARY SUBJECTS
WO2020057541A1 (en) * 2018-09-18 2020-03-26 I-Mab Biopharma Co., Ltd. Anti-ifnar1 antibodies for treating autoimmune diseases
WO2020102043A1 (en) * 2018-11-15 2020-05-22 Ampel Biosolutions, Llc Machine learning disease prediction and treatment prioritization

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087335A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
RS64263B1 (sr) * 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863546A (zh) * 2003-08-04 2006-11-15 布里斯托尔-迈尔斯.斯奎布公司 用可溶性ctla4分子治疗心血管疾病的方法
CN101952454A (zh) * 2008-02-08 2011-01-19 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
CN107110939A (zh) * 2014-09-11 2017-08-29 力保科学公司 使用包括hdl和炎症生物标志相互作用参数的风险参数的心血管风险评估
WO2019043292A1 (en) * 2017-08-29 2019-03-07 Gleap Health Technologies Oy METHODS AND ARRANGEMENT OF THRESHOLD DEVICE OF PHYSICAL ACTIVITY REDUCING THE RISKS OF DIABETES, CARDIOVASCULAR DISEASES, INFLAMMATIONS, DEMENTIA, CANCERS AND MORTALITY IN SEDENTARY SUBJECTS
WO2020057541A1 (en) * 2018-09-18 2020-03-26 I-Mab Biopharma Co., Ltd. Anti-ifnar1 antibodies for treating autoimmune diseases
WO2020102043A1 (en) * 2018-11-15 2020-05-22 Ampel Biosolutions, Llc Machine learning disease prediction and treatment prioritization

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M. BOSHUIZEN等: ""Systemic blocking of the interferon-alpha/beta receptor subunit 1 stimulates arteriogenesis without exacerbating atherosclerosis"", 《ATHEROSCLEROSIS》, vol. 235, no. 2, 22 October 2014 (2014-10-22), pages 27 *
W.I. WHITE等: "ALTERATION OF MEDIATORS OF VASCULAR INFLAMMATION BY ANIFROLUMAB IN THE PHASE IIB MUSE STUDY IN SLE", 《SCIENTIFIC ABSTRACTS》, 14 June 2018 (2018-06-14), pages 136 - 137 *
YUDONG LIU等: "" Cardiovascular disease in systemic lupus erythematosus: an updat"", 《CURRENT OPINION IN RHEUMATOLOGY》, vol. 30, no. 5, 3 August 2018 (2018-08-03), pages 441 - 448 *

Also Published As

Publication number Publication date
WO2021239928A9 (en) 2022-03-17
EP4566667A3 (en) 2025-09-03
WO2021239928A2 (en) 2021-12-02
JP2023527054A (ja) 2023-06-26
AU2021279277A1 (en) 2023-02-02
CA3183611A1 (en) 2021-12-02
US12410254B2 (en) 2025-09-09
EP4157873A2 (en) 2023-04-05
WO2021239928A3 (en) 2022-01-27
IL298299A (en) 2023-01-01
US20240158519A1 (en) 2024-05-16
KR20230018446A (ko) 2023-02-07
EP4566667A2 (en) 2025-06-11
BR112022023438A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
JP6306588B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
Sieb Myasthenia gravis: an update for the clinician
Md Yusof et al. Targeting interleukin-6 in rheumatoid arthritis
Rommer et al. Monoclonal antibodies in treatment of multiple sclerosis
EP4114465B1 (en) Anti-ifnar1 dosing regime for subcutaneous injection
CN104011223A (zh) 使用il-17拮抗剂及psa应答或非应答等位基因治疗银屑病性关节炎(psa)的方法
CN115667309A (zh) 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
US20230074793A1 (en) Treatment with a bispecific antibody that binds ctla4 and pd1
US20220396630A1 (en) Type i interferon inhibition in systemic lupus erythematosus
WO2021250533A1 (en) Methods of treatment using omalizumab or ligelizumab
CN116406296A (zh) 狼疮发作的治疗
Gensicke et al. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis
US20240327529A1 (en) Steroid sparing
US20240368294A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
JP2022527542A (ja) 抗ＩＦＮ－α／ω抗体の投与方法
US20250002591A1 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients
CN118076379A (zh) 狼疮的治疗
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
JP6923594B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
KR20260013475A (ko) 루푸스의 치료
Condon Improving Outcomes in Glomerulonephritis
KR20260060447A (ko) 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230131

WD01 Invention patent application deemed withdrawn after publication